SPOTLIGHT -
EP. 1: Introduction and Global Trends of Gastric Cancer
EP. 2: Genetic Risk, Screening, and Diagnosis for Gastric Cancer
EP. 3: Molecular Testing Used for Gastric Cancer
EP. 4: Factors Determining Initial Treatment Approach for Gastric Cancer
EP. 5: Treatment in HER2-Positive Disease and Dosing Preferences
EP. 6: First-Line Therapy in HER2-Negative Gastric Cancer
EP. 7: Trastuzumab in HER2-Positive Gastroesophageal Cancer
EP. 8: Surgery Options in Locally Advanced Gastric Cancer
EP. 9: Differentiating Among the Types of Surgery
EP. 10: Place for Surgery and Poor Prognosis
EP. 11: Ramucirumab for Progressive Disease in Gastric Cancer
EP. 12: The Role of Immunotherapy in Gastric Cancer
EP. 13: Interpretation of Data on Immunotherapy Use in Gastric Cancer
EP. 14: Novel and Combination Therapies for the Treatment of Gastric Cancer
EP. 15: Drug Development and Final Thoughts
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
